Title: Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study”

Authors: Thomas C. Williams^{1*}, Mark D Lyttle^{2,3}, Steve Cunningham^{4,5}, Ian Sinha^{6,7}, Olivia Swann^{8,9}, Abigail Maxwell-Hodkinson¹⁰ & Damian Roland^{11,12} on behalf of the Paediatric Emergency Research in the UK and Ireland (PERUKI)¹³

Affiliations: ¹Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; ²Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK; ³Emergency Department, Bristol Royal Hospital for Children, Bristol, UK; ⁴Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK; ⁵ Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; ⁶University of Liverpool, UK; ⁷Alder Hey Children's Hospital, Liverpool, UK; ⁸Department of Child Life and Health, University of Edinburgh, Edinburgh, UK; ⁹Department of Paediatric Infectious Diseases and Immunology, Royal Hospital for Children, Glasgow, UK; ¹⁰University of Liverpool Medical School, Liverpool, UK; ¹¹Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, Leicester Royal Infirmary, Leicester, UK, ¹²Sapphire Group, Health Sciences, University of Leicester, Leicester, UK; ¹³PERUKI Site Leads are listed in Supplementary File 1.

***Corresponding Author:** Thomas C Williams, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South EH4 2XU [Thomas.Christie.Williams@ed.ac.uk]

Protocol Version: 1

22

23

24 **Abstract**

25 **Background**

26 Bronchiolitis (most frequently caused by Respiratory Syncytial Virus; RSV) is a common
 27 winter disease predominantly affecting children under one year of age. It is a common reason
 28 for presentations to an Emergency Department (ED) and frequently results in hospital
 29 admission, contributing to paediatric units approaching or exceeding capacity each winter.
 30 During the SARS-CoV-2 pandemic, the circulation of RSV was dramatically reduced in the
 31 United Kingdom and Ireland. Evidence from the Southern Hemisphere and other European
 32 countries suggests that as social distancing restrictions for SARS-CoV-2 are relaxed, RSV
 33 infection returns, causing delayed or even summer epidemics, with different age distributions.

34 **Study question**

35 The ability to track, anticipate and respond to a surge in RSV cases is critical for planning
 36 acute care delivery. There is an urgent need to understand the onset of RSV spread at the
 37 earliest opportunity. This will influence service planning, to inform clinicians whether the
 38 population at risk is a wider age range than normal, and whether there are changes in disease
 39 severity. This information is also needed to inform decision on the timing of passive
 40 immunisation of children at higher risk of hospitalisation, intensive care admission or death
 41 with RSV infection, which is a public health priority.

42 **Methods and likely impact**

43 This multi-centre prospective observational cohort study will use a well-established research
 44 network (Paediatric Emergency Research in the UK and Ireland, PERUKI) to report in real
 45 time cases of RSV infection in children aged under two years, through the collection of
 46 essential, but non-identifying patient information. Forty centres will gather initial data on age,
 47 index of multiple deprivation quintile, clinical features on presentation, and co-morbidities.
 48 Each case will be followed up at 7 days to identify treatment, viral diagnosis and outcome.
 49 Information be released on a weekly basis and used to support clinical decision making.

50 **Keywords**

51 COVID-19; Respiratory Syncytial Virus; Bronchiolitis; Infants; Children; Palivizumab

52

53 **Main body**

54 ***Introduction***

55 Non-pharmaceutical interventions (NPIs) implemented to slow or eliminate the spread of
 56 SARS-CoV-2 have also had dramatic off-target consequences on transmission of other
 57 respiratory viruses, in particular Respiratory Syncytial Virus (RSV) in children. RSV
 58 infection can cause a clinical syndrome termed bronchiolitis, most commonly in infants under
 59 one year of age, and lower respiratory infection associated with wheeze in older children,
 60 typically under two years of age. In a typical year in England, RSV bronchiolitis causes
 61 significant morbidity, leading to an estimated 36,028 annual admissions for RSV, mainly in
 62 infants under 1 year of age;¹ every year 0.1% of all infants under 1 are admitted to paediatric
 63 intensive care units (PICUs) with a diagnosis of bronchiolitis.² In the years preceding
 64 2020/21, RSV infections in the United Kingdom and Ireland saw consistent seasonal peaks in
 65 infection and hospitalisation, with cases generally starting to rise in September, peaking in
 66 November/December, and falling to summer levels by April.¹ As such, when lockdown
 67 measures were implemented during the early spring of 2020, the RSV season was already in
 68 recession in the Northern hemisphere and no clear impact was seen on RSV disease burden.
 69 However, in the corresponding Southern Hemisphere winter of 2020, the NPIs led to
 70 dramatically reduced cases and admissions of paediatric RSV and influenza in Australia,³
 71 New Zealand,⁴ Chile and South Africa.⁵ An associated reduced rate of admissions to
 72 Paediatric Intensive Care Unit (PICU) across South America, mainly driven by a reduction in
 73 respiratory diagnoses, was also observed.⁶

74

75 Hierarchical variance of NPIs over time have interrupted transmission of some, but not all,
 76 respiratory viruses.⁷ In the United Kingdom, test positivity for RSV in the Respiratory
 77 DataMart system has remained at less than 1% throughout the winter of 2020/21 (last data 11
 78 April 2021).⁸ Conversely, rhinovirus infections continued throughout the Southern and
 79 Northern Hemisphere winter seasons.^{8,9} A typical annual spike in rhinovirus infections in
 80 children was observed with the return to schools in England in September 2020,⁸ and PICUs
 81 saw ongoing admissions for rhinovirus induced wheeze and bronchiolitis in the
 82 autumn/winter of 2020 despite lockdown measures [NHS Lothian data, unpublished].

83

84 Both observational and modelling studies suggest that RSV will arise out of season in the
 85 Northern hemisphere and may have a greater clinical impact.¹⁰ Four Australian states, which

after an initial lockdown imposed few physical distancing measures with re-opened schools, have now experienced delayed annual RSV epidemic peaks. The delayed peak in Western Australia, where infections rates surged during local Spring-Summer (September-December), was associated with even higher case rates than normally seen during winter, despite no change in testing practices.¹¹ Some European countries such as France have already seen evidence of a delayed RSV season, with all French regions now having reported bronchiolitis case rates at epidemic levels.¹²

From a clinical perspective, it is not possible to distinguish the viral aetiology of lower respiratory tract infection, with the exception of greater probability by season of infection. With the uncoupling of RSV and seasonality observed as an impact of NPIs, there is an urgent requirement to track RSV infection for season onset and to observe the impact on a larger unexposed at risk population. It is likely that when RSV returns to the United Kingdom and Ireland in 2021 it will not follow its usual predictable seasonal pattern, particularly if lockdown measures are relaxed rapidly as SARS-CoV-2 immunisation coverage increases. Reasons why RSV might display unusual disease dynamics include a lack of circulation in the general population leading to a reduction of transplacental antibodies and passive immunity for neonates, and the fact that children born after February 2020 will most likely not have been exposed to circulating RSV, thus reducing adaptive immune response to the virus when encountered. RSV infection is also associated with recurrent wheeze as a longer-term post infectious morbidity. A higher proportion of children affected by RSV may increase the subsequent healthcare burden of post infectious wheeze giving a much longer-term burden on health services.

The objective of this study is to monitor RSV disease in children under two years of age attending emergency departments across the UK and Ireland and examine the impact on timing, age and severity of clinical presentations as NPI restrictions are reduced throughout the UK and Ireland in 2021.

Study Protocol

This protocol is structured in keeping with the principles of the STROBE statement (strobe-statement.org/).

118 *How the sample is to be selected*

119 A national multi-centre prospective observational cohort study will be carried out through the
120 PERUKI (Paediatric Emergency Research in the UK and Ireland) Network¹³ with forty
121 departments having committed to participating in the study. All children meeting the
122 inclusion criteria below will be eligible.

123 *Inclusion criteria*

124 Children under two years of age presenting to participating emergency departments with
125 clinical features of bronchiolitis (cough, tachypnoea or chest recession, and wheeze or
126 crackles on chest auscultation)¹⁴ or a first episode of acute viral wheeze.

127 *Exclusion criteria*

128 Children with previous episodes of wheeze responsive to bronchodilator, suggesting an
129 underlying diagnosis of recurrent wheeze of early childhood.

130 *Data collection*

131 We will collect data at two time points: baseline (date of presentation to a participating ED)
132 and seven days later.

133 Clinicians identifying a case for inclusion will keep a local log of participants that contain
134 patient identifiable characteristics cross referenced to a study number. The study number
135 alone is used in all communication/data entry with the study team. An email after 7 days to
136 the submitting clinician will prompt data entry at this point.

137 Anonymised data will be entered to a secure online database (REDCap data capture tool)^{15,16}
138 (see below), by clinicians providing acute care within the ED.

139 *Variables to be measured*

140 At baseline, data including patient demographics, presenting characteristics, acuity,
141 investigations and treatments will be obtained (see Supplementary File 2), as will data on the
142 number of siblings and travel. An external link will enable clinicians to enter a full postcode
143 derived index of multiple deprivation score for database entry.

144 At 7 days data will include the child's ultimate outcome (discharged or admitted), highest
145 acuity dependency (the ward they were placed on if admitted: Normal, High Dependency or

Intensive Care), whether care is ongoing, patient was discharged or died and (if obtained) what viruses were identified by PCR (see Supplementary File 3).

RSV status will be identified by either Nasopharyngeal Aspirate (NPA) (a) point of care testing (rapid viral testing where available) at baseline presentation to ED, or (b) by laboratory PCR testing, if either is performed as part of standard care.

Sample size calculation

This is a convenience sample cohort study and as such a sample size is not calculated. However, the most recent bronchiolitis peak in France (epidemiological week 13, to 8 April 2021), involved 2,433 emergency department (ED) attendances and 953 hospital admissions in children under the age of 2 years, with a total of ~16,000 ED attendances and ~6,000 admissions since the start of 2021.¹² The combined population of the United Kingdom and Ireland is 72 million, roughly equivalent to that of France (67 million). The PERUKI sites already enrolled in this study are estimated to provide care for 25 % of the total paediatric population, and if a similar trend is seen to France we would therefore expect to recruit 4,000 infants and children in the build up to the peak of an RSV epidemic. By site this would be a mean of ~100 patients over 3 months, or approximately a patient a day per site. Previous PERUKI surveillance studies have recruited > 1,000 patients in short time scales (1-2 months).

Study registration

The trial will be prospectively registered on ISCRTN Registry (<https://www.isrctn.com/>).

Primary outcomes to be measured, as well as a list of secondary outcomes

Primary outcome

To report the timing, frequency and clinical severity of RSV infection in children under two years of age presenting to hospitals in the UK and Ireland.

Secondary outcomes

- i. To report the excess morbidity of clinical presentations at ED with respiratory disease by inclusion criteria by month of presentation (compared to published literature/health data sources).
- ii. To report the geographical timing and spread of RSV infection across the UK.

- iii. To identify differences in severity of illness and patient population affected by RSV in relation to typical seasonal ranges in the published literature.
- iv. To provide data to support and corroborate current RSV surveillance systems (i.e. Respiratory Datamart <https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports>) and the Emergency Department Syndromic Surveillance System (EDSSS). (<https://www.gov.uk/government/publications/emergency-department-weekly-bulletins-for-2021>).
- v. To provide data to support decision making by government agencies (Joint Committee on Vaccination and Immunisation) in relation to the prescription of out of season Palivizumab for high risk children.
- vi. To provide data to support estimates of potential longer-term impact of changes in severity of illness and patient populations on health (long term recurrent wheeze) and associated healthcare resources.

Data analysis and statistical plan

- i. Demographics, regional frequencies, incidence estimates and logistic regression will be performed according to a Statistical Analysis Plan (SAP) in place prior to full data analysis. This will include:
- ii. *Descriptive statistics*
 - a. Weekly incidence (broken down nationally and regionally) calculated for population at risk for each Emergency Department.
 - b. Median age, co-morbidities, index of multiple deprivation, presenting features of recruited patients, compared to previous population studies to identify if similar age, spectrum of co-morbidities and presenting clinical features to previous epidemics.
 - c. Proportion of RSV vs non-RSV of those tested.
- iii. *Identification of risk factors for severe disease*
 - a. A number of metrics will be examined as proxy measures for severity including:
 - i. Median saturations in air at presentation and frequency of attendance with SpO₂ <94% or <92% in room air.
 - ii. Median respiratory rate (with reference to age as per Paediatric Early Warning Score) at presentation.¹⁷

- 208 iii. Blood gas composition (median H⁺ and pCO₂ measurements) at
209 presentation.
- 210 iv. Proportion of children admitted to hospital and of those the proportion
211 admitted to standard care / HDU / PICU.
- 212 v. Proportion of children requiring respiratory support (supplementary
213 oxygen, high flow oxygen, CPAP, BiPAP or invasive ventilation).
- 214 vi. Length of stay.
- 215 b. Multivariate logistic regression analyses using random effects model
216 (recruiting site, availability of on-site PICU facility) to examine risk factors
217 for hospitalisation, level of ventilatory support and PICU admission. Risk
218 factors will be compared to predictors of severe disease published in
219 population studies previously.
- 220 iv. *Spatio-temporal dynamics of the 2021 epidemic*
- 221 a. Travel histories will be used to identify whether RSV is seeded into
222 community in a number of separate introduction events, or spreads locally.

223 *Details of any ethical issues relating to the study (and of the ethical approval received)*

224 This prospective observational surveillance study needs to be able to rapidly collate data that
225 will enable other researchers and health services to make informed decisions about the extent
226 of any RSV surge. For this reason, and the fact that the data being obtained is already
227 obtained as part of the clinical record, we will not be asking for consent from families and
228 carers. The clinician will only enter data regarding the outcomes of the child and no
229 identifying information will be recorded. The patient's study number will be linked to the
230 local hospital number to allow outcome data to be retrieved. This information will be held by
231 the recruiting site only in secure research lockers in each Emergency Department and only
232 available to appropriately trained staff or research nurses.

233 None of the data recorded centrally by the study team will mean the patient is identifiable,
234 and there are no specific details recorded that would make it possible to determine any
235 individual child by proxy. This approach has been successfully adopted in other rapidly
236 deployed studies the authors have been involved in. The security of the REDCap system we
237 are using to collate data will add additional data protection safeguards.

238 The study will be submitted for Integrated Research Application System (IRAS) approval
239 with University Hospitals of Leicester NHS Trust as the Study Sponsor, IRAS ID 297802.

240 *Data input, storage and management*

241 Anonymised data will be entered using the validated online data entry software REDCap.
 242 (Research Electronic Data Capture tools) following the clinical report forms provided in the
 243 appendix (Supplementary Files 2 and 3). This software (REDCap) is hosted on the University
 244 Hospitals Bristol and Weston NHS Foundation Trust (UHBW) secure server, accessible on
 245 the Health and Social Care Network (HSCN) that is managed by NHS Digital. All research
 246 data reside within the hosting institution, and there will be a data transfer agreement made
 247 between University Hospitals of Leicester NHS Trust, Edinburgh University and University
 248 Hospitals Bristol and Weston NHS Foundation Trust in order to allow transfer of data on
 249 completion of data entry and cleaning. Processing of data will be undertaken on instruction of
 250 the Data Controller. The study Sponsor organisation (University Hospitals of Leicester NHS
 251 Trust) will be the Data Controller throughout, and University Hospitals Bristol and Weston
 252 NHS Foundation Trust will have Joint Controllorship for the duration of data entry and
 253 cleaning. REDCap uses a granular security model so that users can only review the data they
 254 have been explicitly authorised to access. REDCap also provides a comprehensive log/audit
 255 feature that records all individual changes with a date/time stamp and a change owner. Data
 256 that are captured and stored will only be available via the information technology systems
 257 linked to the HSCN which is the current validated system used by NHS Trusts to share and
 258 store patient information.

259

260 *Plans for dissemination of the study outcome (including the associated data) once completed.*

261 Data will be presented in:

- 262 i. Data submissions to the regulatory authorities and local study teams, including an
 263 interactive online dashboard.
- 264 ii. Conference presentations.
- 265 iii. Peer reviewed scientific journals.
- 266 iv. Collaboration with educational websites with international social media reach
 267 (www.dontforgetthebubbles.com).
- 268 v. Engagement with the RSV patient network, part of the RESCEU Consortium
 269 (<http://resc-eu.org/>).

270 *Conclusions*

There is an urgent need to better understand the effects of non-pharmaceutical interventions on the transmission and disease dynamics of Respiratory Syncytial Virus, a major cause of morbidity in infants in the United Kingdom. BronchStart is a multi-centre observational study embedded within the PERUKI network which will inform the immediate clinical response to a delayed RSV peak, improve our understanding of how RSV is seeded and spreads within the United Kingdom, and inform the implementation of future RSV immunisation campaigns.

Ethics policies

The study protocol has been submitted to Integrated Research Application System; in view of the urgency needed to take this project forward, and the fact that no patient identifiable information will be collected, we believe it to be exempt from Research Ethics Committee (REC) Review. This is also in keeping with the Control of Patient Information Notice (Covid-19 – Notice under Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002) last reviewed 3rd February 2021.

Data availability

As this is a study protocol no data are yet available. Once available, anonymised, non-patient identifiable data will be stored on a RedCap server hosted by University of West of England, Bristol, United Kingdom (See Data input, storage and management).

Author contributions

Williams TC: Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing

Lyttle MD: Conceptualization, Methodology, Project Administration, Software, Writing – Original Draft Preparation, Writing – Review & Editing

Cunningham S: Conceptualization, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing

Sinha I: Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing

Swann O: Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing

Maxwell-Hodkinson A : Conceptualization, Methodology, Writing – Review & Editing

Roland D: Conceptualization, Methodology, Project Administration, Writing – Original Draft
Preparation, Writing – Review & Editing

PERUKI Site Leads: Conceptualization, Writing – Review & Editing

Competing Interests

No competing interests were disclosed.

Grant Information

Dr. Williams is the recipient of a Wellcome Trust Award [204802/Z/16/Z].

Acknowledgements

The authors would like to thank Mai Bacquedano for technical support in the launch of the REDCap survey tool and ongoing data management.

Supplementary material

Supplementary File 1 lists the PERUKI investigators who will be coordinating local data entry.

Supplementary File 2 and 3 show the full questionnaires to be completed by clinicians/researchers, including the logic branching trees for questions asked.

References

- 1 Lewis KM, De Stavola B, Hardelid P. Geospatial and seasonal variation of bronchiolitis in England: a cohort study using hospital episode statistics. *Thorax* 2020; **75**: 262–268.
- 2 Green CA, Yeates D, Goldacre A, *et al.* Admission to hospital for bronchiolitis in England: Trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. *Arch Dis Child* 2016; **101**: 140–6.
- 3 Britton PN, Hu N, Saravanos G, *et al.* COVID-19 public health measures and respiratory syncytial virus. *Lancet Child Adolesc Heal* 2020; **4**: e42–3.
- 4 Huang QS, Wood T, Jelley L, *et al.* Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. *Nat*

327 *Commun* 2021; **12**: 1–7.

328 5 Olsen SJ, Azziz-Baumgartner E, Budd AP, *et al.* Decreased Influenza Activity During
329 the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020.
330 *MMWR Morb Mortal Wkly Rep* 2020; **69**: 1305–9.

331 6 Vásquez-Hoyos P, Diaz-Rubio F, Monteverde-Fernandez N, *et al.* Reduced PICU
332 respiratory admissions during COVID-19. *Arch Dis Child* 2020; **0**: archdischild-2020-
333 320469.

334 7 Williams TC, MacRae C, Swann O V, *et al.* Indirect effects of the COVID-19
335 pandemic on paediatric healthcare use and severe disease: a retrospective national
336 cohort study. *Arch Dis Child* 2021; **0**: archdischild-2020-321008.

337 8 Public Health England. Weekly national Influenza and COVID-19 surveillance report.
338 2021; published online May 15.
339 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachmen](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/978131/Weekly_Flu_and_COVID-19_report_w15.pdf)
340 [t_data/file/978131/Weekly_Flu_and_COVID-19_report_w15.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/978131/Weekly_Flu_and_COVID-19_report_w15.pdf) (accessed April 16,
341 2021).

342 9 Nicolaides Pathology S. Respiratory Virus Report 2020. 2020.

343 10 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of
344 COVID-19 nonpharmaceutical interventions on the future dynamics of endemic
345 infections. *Proc Natl Acad Sci* 2020; **117**: 30547–53.

346 11 Foley DA, Yeoh DK, Minney-Smith CA, *et al.* The Interseasonal Resurgence of
347 Respiratory Syncytial Virus in Australian Children Following the Reduction of
348 Coronavirus Disease 2019–Related Public Health Measures. *Clin Infect Dis* 2021;
349 published online Feb 17. DOI:10.1093/cid/ciaa1906.

350 12 Sante Publique France. Bulletin épidémiologique bronchiolite, semaine 14. Saison
351 2020-2021. 2021. [https://www.santepubliquefrance.fr/maladies-et-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-national/bulletin-epidemiologique-bronchiolite-semaine-14.-saison-2020-2021)
352 [traumatismes/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-](https://www.santepubliquefrance.fr/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-national/bulletin-epidemiologique-bronchiolite-semaine-14.-saison-2020-2021)
353 [national/bulletin-epidemiologique-bronchiolite-semaine-14.-saison-2020-2021](https://www.santepubliquefrance.fr/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-national/bulletin-epidemiologique-bronchiolite-semaine-14.-saison-2020-2021)
354 (accessed April 16, 2021).

355 13 Lyttle MD, O’Sullivan R, Hartshorn S, Bevan C, Cleugh F, Maconochie I. Pediatric
356 Emergency Research in the UK and Ireland (PERUKI): Developing a collaborative for

357 multicentre research. *Arch Dis Child* 2014; **99**: 602–3.

358 14 NICE. 1 Recommendations | Bronchiolitis in children: diagnosis and management |
359 Guidance | NICE. [https://www.nice.org.uk/guidance/ng9/chapter/1-](https://www.nice.org.uk/guidance/ng9/chapter/1-Recommendations#assessment-and-diagnosis)
360 Recommendations#assessment-and-diagnosis (accessed April 2, 2021).

361 15 Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an
362 international community of software platform partners. *J Biomed Inform* 2019; **95**.
363 DOI:10.1016/j.jbi.2019.103208.

364 16 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
365 data capture (REDCap)-A metadata-driven methodology and workflow process for
366 providing translational research informatics support. *J Biomed Inform* 2009; **42**: 377–
367 81.

368 17 PEWS. [https://ihub.scot/improvement-programmes/scottish-patient-safety-programme-](https://ihub.scot/improvement-programmes/scottish-patient-safety-programme-spsp/spsp-programmes-of-work/maternity-and-children-quality-improvement-collaborative-mcqc/paediatric-care/pews/)
369 [spsp/spsp-programmes-of-work/maternity-and-children-quality-improvement-](https://ihub.scot/improvement-programmes/scottish-patient-safety-programme-spsp/spsp-programmes-of-work/maternity-and-children-quality-improvement-collaborative-mcqc/paediatric-care/pews/)
370 [collaborative-mcqc/paediatric-care/pews/](https://ihub.scot/improvement-programmes/scottish-patient-safety-programme-spsp/spsp-programmes-of-work/maternity-and-children-quality-improvement-collaborative-mcqc/paediatric-care/pews/) (accessed April 14, 2021).